Identifying and modulating molecular pathways that mediate nervous system plasticity
The present invention provides methods for identifying genes and pathways involved in plasticity. The invention applies some of these methods to identify genes that are differentially regulated in at least a portion of the nervous system of an individual subjected to conditions known to result in altered nervous system plasticity, i.e., dark rearing (DR) or monocular deprivation (MD). The genes are targets for pharmacological agents that modify plasticity. The invention also identifies biological pathways that are enriched in genes that are differentially regulated under conditions known to result in altered nervous system plasticity. The present invention further provides methods and compositions for modifying plasticity in the nervous system of a subject. The invention includes a method for modifying plasticity in the nervous system of a subject comprising administering a plasticity-modifying agent to the subject, wherein the plasticity-enhancing agent modulates a gene or pathway that is differentially regulated in developmental conditions that alter nervous system plasticity (e.g., DR or MD). The methods and compositions may be administered to a subject suffering from damage to the nervous system or from a neuropsychiatric disorder in order to enhance recovery, reorganization, or function of the nervous system. The methods optionally include administering a proteolysis-enhancing agent to the subject.
1. A method for promoting recovery or reorganization in the nervous system of a subject suffering from a neurodevelopmental disorder, the method comprising administering to the subject a tissue plasminogen activator (tPA) and an insulin like growth factor-1 (IGF 1), wherein the neurodevelopmental disorder is selected from the group consisting of: autism, dyslexia, Asperger's syndrome, pervasive developmental disorders—not otherwise specified, Tourette's syndrome, and personality disorders.
2. The method of claim 1 , wherein the tissue plasminogen activator (tPA) and insulin-like growth factor-1 (IGF-1) are administered following diagnosis of the neurodevelopmental disorder.
3. The method of claim 1 or claim 2 , wherein the tissue plasminogen activator (tPA) and insulin-like growth factor-1 (IGF-1) are administered together or separately following diagnosis of the specific neurodevelopmental disorder.
4. The method of claim 1 , wherein the neurodevelopmental disorder is autism.
5. A method for promoting recovery or reorganization in the nervous system of a subject suffering from a neuropsychiatric disorder, comprising administering to the subject a tissue plasminogen activator (tPA) and an insulin like growth factor-1 (IGF 1).
6. The method of claim 5 , wherein the tissue plasminogen activator (tPA) and insulin-like growth factor-1 (IGF-1) are administered following diagnosis of the neuropsychiatric disorder.
7. The method of claim 5 or claim 6 , wherein the tissue plasminogen activator (tPA) and insulin-like growth factor-1 (IGF-1) are administered together or separately following diagnosis of the specific neuropsychiatric disorder.
8. The method of claim 5 , wherein the neuropsychiatric disorder is selected from the group consisting of: schizophrenia and bipolar disorders.
9. The method of claim 5 , wherein the neuropsychiatric disorder is schizophrenia.